TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22752440

Group type: COMPARATOR
Intervention: Mg-0 (100 mL of normal saline)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mg-25 (25 mg/kg magnesium sulfate)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mg-50 (50 mg/kg magnesium sulfate)
Number of subjects: 88
Study: 20008620

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg twice daily
Number of subjects: 50
Study: 18451774

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (1 g vitamin C/800 IU vitamin E)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate weight loss diet (HF)
Number of subjects: 19
Study: 15989982

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural block (CSEB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural block (EB)
Number of subjects: 80
Study: 12854881

Group type: EXPERIMENTAL
Intervention: Cetirizine (30 mg a day, 3 times a day for 15 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10574595

Group type: EXPERIMENTAL
Intervention: Computer-assisted PAPNET analysis
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Conventional screening
Number of subjects: 846
Study: 8916975

Group type: COMPARATOR
Intervention: Antigenemia-guided ganciclovir treatment (placebo group)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ganciclovir administered at engraftment (ganciclovir group)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Antigenemia-guided ganciclovir treatment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Ganciclovir administered at engraftment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 226
Study: 1726208

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200mg twice daily for 7 to 14 days
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 400mg twice daily for 7 to 14 days
Number of subjects: 251

Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 251
Study: 6356004

Group type: EXPERIMENTAL
Intervention: Bicillin C‐R, 50,000 U/kg intramuscularly, followed by penicillin V, 100 mg/kg/d, orally four times a day for three days
Number of subjects: 96

Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 96
Study: 30423132

Group type: EXPERIMENTAL
Intervention: Acylcarnitine profile including short- and long-chain acylcarnitines
Number of subjects: 945

Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: C4OH-carnitine increase
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Model including acylcarnitines
Number of subjects: 945
Study: 30233001

Group type: EXPERIMENTAL
Intervention: Corrected‐Assisted‐Synchronized‐Periodic (CASP) therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional passive stretching exercises
Number of subjects: 61
Study: 25029567

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 63
Study: 24942646

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mcg oral Se tablets, twice daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 22318373

Group type: EXPERIMENTAL
Intervention: Physical therapy (9 sessions over 6 weeks including joint mobilization, exercises, and massage)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 49
Study: 20051951

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening with PSA serum test (cutoff level of 4.0 ng/ml)
Number of subjects: 0
Study: 18034989

Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Losartan (50‐100 mg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 188
Study: 16220762

Group type: EXPERIMENTAL
Intervention: Transducer-tipped intrauterine pressure catheter
Number of subjects: 249

Group type: COMPARATOR
Intervention: Air-coupled intrauterine pressure catheter
Number of subjects: 249
Study: 11339498

Group type: EXPERIMENTAL
Intervention: Filgrastim (rhG-CSF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9734619

Group type: EXPERIMENTAL
Intervention: Recombinant insulin‐like growth factor‐1 (rhIGF‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of recombinant growth hormone (rhGH) plus recombinant IGF‐1
Number of subjects: 8
Study: 8112242

Group type: EXPERIMENTAL
Intervention: PHT before test sessions
Number of subjects: 50

Group type: COMPARATOR
Intervention: PHT after test sessions
Number of subjects: 50
Study: 2847524

Group type: EXPERIMENTAL
Intervention: iproplatin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 132
Study: 1139766

Group type: EXPERIMENTAL
Intervention: Prick test with allergen extracts
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Serum level of allergen specific IgE
Number of subjects: 153

Group type: COMPARATOR
Intervention: Negative prick test reaction
Number of subjects: 153

Group type: COMPARATOR
Intervention: Serum tests results for IgE specific to allergens
Number of subjects: 153
Study: 30794553

Group type: EXPERIMENTAL
Intervention: Knee guard device (magnetophoresis delivering Glucosamine, Chondroitin, and Hyaluronic Acid)
Number of subjects: 114

Group type: COMPARATOR
Intervention: NSAID gel (diclofenac sodium 1%)
Number of subjects: 114
Study: 27503605

Group type: EXPERIMENTAL
Intervention: Remind-to-move (RTM) treatment; 25 children, 75 hours over 3 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT); 24 children, 75 hours over 3 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional rehabilitation; 24 children
Number of subjects: 73
Study: 26706662

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levonorgestrel-containing intrauterine device (LNG-IUD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with BMI<35
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with BMI≥35
Number of subjects: 60
Study: 24985000

Group type: EXPERIMENTAL
Intervention: Probiotics (B. animalis subspecies lactis MB 2409, B. bifidum MB 109B, and B. longum subspecies longum BL04) for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 23186556

Group type: EXPERIMENTAL
Intervention: Mindfulness- and body-psychotherapy-based group treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (waiting time)
Number of subjects: 36
Study: 19287181

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study: 17213825

Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) determination
Number of subjects: 30194

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE)
Number of subjects: 30194

Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 30194
Study: 15609592

Group type: EXPERIMENTAL
Intervention: Chinese herbs (CH)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 53
Study: 11761341

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study: 9052580

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) replacement therapy (2 mg/day for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8329264

Group type: EXPERIMENTAL
Intervention: 0.9% saline with adrenaline 1:200,000
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline 1:200,000
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% lignocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 80
Study: 3520797

Group type: EXPERIMENTAL
Intervention: Endoscopists with knowledge of radiologic diagnosis
Number of subjects: 156

Group type: COMPARATOR
Intervention: Endoscopists without knowledge of radiologic diagnosis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Overall agreement for duodenal ulcer
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Overall agreement for deformity of the duodenal bulb
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Overall agreement for duodenitis
Number of subjects: 156
Study: 30177372

Group type: EXPERIMENTAL
Intervention: NTR + TA
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: NTR + DVH + TA
Number of subjects: 351
Study: 27835719

Group type: EXPERIMENTAL
Intervention: Taurine 4 g once daily for 12 weeks
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 24963662

Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite-infected Anopheles mosquitoes (2-4 bites)
Number of subjects: 16
Study: 22900524

Group type: EXPERIMENTAL
Intervention: Information Aid (IA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed access to IA (Control)
Number of subjects: 45
Study: 21111093

Group type: EXPERIMENTAL
Intervention: Choice, Control & Change curriculum
Number of subjects: 562

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 562
Study: 19074257

Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 15
Study: 17162333

Group type: EXPERIMENTAL
Intervention: Solu Q10
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oily dispersions and crystalline CoQ10
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All formulations including Solu Q10
Number of subjects: 54
Study: 12796021

Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected in peripheral blood after adjuvant chemotherapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected after adjuvant cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected in patients with four or more involved lymph nodes
Number of subjects: 161
Study: 10824554

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of anticancer agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and thoracic irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent administration of anticancer agents with thoracic irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents demonstrating antitumor activity against lung cancer
Number of subjects: 0
Study: 8648471

Group type: EXPERIMENTAL
Intervention: Induced hypotensive anesthesia (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Anesthesia with no attempt to deliberately reduce blood pressure (n = 25)
Number of subjects: 50
Study: 8504648

Group type: EXPERIMENTAL
Intervention: Papaverine (60 mg/500 mL)
Number of subjects: 239

Group type: COMPARATOR
Intervention: No additive
Number of subjects: 239
Study: 3032033

Group type: EXPERIMENTAL
Intervention: Chemotherapy with chest radiation therapy (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine; chest irradiation to 40 Gy in 15 fractions over 3 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy alone (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine)
Number of subjects: 96
Study: 29380957

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIE)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MOD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sedentary Control (CON)
Number of subjects: 5
Study: 26906747

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg primaquine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.0625 mg/kg primaquine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg primaquine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (0 mg/kg primaquine)
Number of subjects: 81
Study: 24039119

Group type: EXPERIMENTAL
Intervention: FeNO group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 99
Study: 22990510

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 19190547

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg, 3 monthly injections)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab plus PDT (0.5 mg, 3 monthly injections + 1 session of PDT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone plus PDT (4 mg, 1 injection + 1 session of PDT)
Number of subjects: 37
Study: 17277240

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (twice‐weekly treadmill assessments from 4 to 10 weeks postoperatively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preoperative and postoperative care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 0
Study: 15621576

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11895149

Group type: EXPERIMENTAL
Intervention: Immunonutrition (arginine, n‐3‐fatty acids, and nucleotides)
Number of subjects: 29
Study: 9021436

Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8198269

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (15 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (22.5 mg)
Number of subjects: 40
Study: 3069457

Group type: EXPERIMENTAL
Intervention: Guar
Number of subjects: 15
Study: 29193553

Group type: EXPERIMENTAL
Intervention: AB-102 (novel topical solution containing a high concentration of a weak α1 agonist)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phenylephrine (previously used topical treatment)
Number of subjects: 100
Study: 26692322

Group type: EXPERIMENTAL
Intervention: High Intake (HI) group, consuming three cups (600 mL) of black tea per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low Intake (LI) group, administered 1 cup (200 mL) of black tea per day
Number of subjects: 30
Study: 24240972

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 217

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 217
Study: 23799688

Group type: EXPERIMENTAL
Intervention: Postpartum doula support
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Peer telephone support
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 20506988

Group type: EXPERIMENTAL
Intervention: Visian Toric Implantable Collamer Lens (TICL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 88
Study: 18400558

Group type: EXPERIMENTAL
Intervention: CHOP-like chemotherapy alone
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: CHOP-like chemotherapy with rituximab
Number of subjects: 823
Study: 16809805

Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg on day 1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dolasetron 100 mg plus aprepitant 125 mg on day 1, aprepitant 80 mg on days 2-3
Number of subjects: 12
Study: 12787235

Group type: EXPERIMENTAL
Intervention: Changing Childbirth initiative (pilot scheme)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional maternity care (control)
Number of subjects: 200
Study: 11006067

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Perceiving fewer barriers to getting a FS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Having a physician recommend a FS
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Precontemplation stage of adoption
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: FS beliefs, FS barriers, risk of developing colorectal cancer, worry about getting colorectal cancer, and physician recommendation to get a FS
Number of subjects: 202
Study: 8797414

Group type: EXPERIMENTAL
Intervention: Saralasin, 5 micrograms/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1497392

Group type: EXPERIMENTAL
Intervention: Heparin with warfarin
Number of subjects: 199

Group type: COMPARATOR
Intervention: Heparin only
Number of subjects: 199
Study: 6736589

Group type: EXPERIMENTAL
Intervention: Mother's voice
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unknown voices
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mother's voice (after excluding cold voices)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Other women (after excluding cold voices)
Number of subjects: 25
Study: 31170332

Group type: EXPERIMENTAL
Intervention: Circulating sclerostin levels (genetic instrument derived from SNPs)
Number of subjects: 426824
Study: 29651784

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for CRF
Number of subjects: 81

Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 81
Study: 26815179

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) 300 mg · kg(‐1) in 450 ml of flavored water
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (NaCl 270 mg · kg(‐1) body mass)
Number of subjects: 11
Study: 24440102

Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 30
Study: 22157131

Group type: EXPERIMENTAL
Intervention: SAAF-T program (family-centered preventive intervention)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 502
Study: 20698991

Group type: EXPERIMENTAL
Intervention: Biomechanical device treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (identical foot-worn platform without biomechanical elements)
Number of subjects: 0
Study: 17576843

Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 25 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 250 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16386155

Group type: EXPERIMENTAL
Intervention: 10-day training program of walking 1800 feet per day with instructions to take long steps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study: 12006727

Group type: EXPERIMENTAL
Intervention: Complementary treatment (herbal remedy Sinupret and homeopathic remedy Cinnabaris 3X)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional treatment (antibiotics, secretolytics, symptomimetics)
Number of subjects: 63
Study: 10541897

Group type: EXPERIMENTAL
Intervention: One-site approach (superior tunnel phacoemulsification under a scleral flap with subsequent trabeculectomy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two-site approach (temporal corneal phacoemulsification combined with a separate-incision superior trabeculectomy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study: 7546837

Group type: EXPERIMENTAL
Intervention: High-dose therapy with autologous bone marrow stem cell support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional doses of polychemotherapy
Number of subjects: 0
Study: 2182959

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg p.o.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg p.o.) + Naloxone (2.8 mg i.v. in 5 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (oral and i.v.)
Number of subjects: 10
Study: 6456068

Group type: EXPERIMENTAL
Intervention: Mezlocillin (1.5 gm) administered intramuscularly every six hours for seven days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ticarcillin (2 gm) administered intramuscularly every six hours for seven days
Number of subjects: 60
Study: 31688089

Group type: EXPERIMENTAL
Intervention: CAncer Pain management support Program
Number of subjects: 94
Study: 31689581

Group type: EXPERIMENTAL
Intervention: Nutritional advice and seedlings of Calliandra calothyrsus and Sesbania sesban
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Calliandra or Sesbania supplementation
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no Calliandra or Sesbania supplementation)
Number of subjects: 155
Study: 28790162

Group type: EXPERIMENTAL
Intervention: Annual screening examinations including laboratory assessments and various imaging modalities (e.g. CT, MRI, scintigraphy and EUS) for MEN1 patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of different and new imaging methods regarding their sensitivity and utility in MEN1 patients.
Number of subjects: 0
Study: 25849094

Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-Audience Response System (non-ARS)
Number of subjects: 100
Study: 22898358

Group type: EXPERIMENTAL
Intervention: SILCS single‐sided gel delivery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SILCS double‐sided gel delivery
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vaginal applicator
Number of subjects: 3
Study: 22295535

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg over 10 min, then 0.4 microg/(kg x h) for 30 min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study: 19098010

Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index (ABPI) over 0.6
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 133